DPYD Pharmacogenomics Testing

All patients, prior to commencing treatment with a fluoropyrimidine based therapy (5- fluorouracil, capecitabine or tegafur) should be screened for the following four DPYD gene variants (c.1905+ 1G>A, c.1679T>G p.(Ile560Ser), c.2846A>T p.(Asp949Val), c.1129–5923C>G) which have been associated with fluoropyrimidine-associated toxicity.

DPYD testing is provided by all 7 Genomic Laboratory Hubs across England. Details on the testing strategy and criteria for testing at the West Midlands Regional Genetics Laboratory can be found in the DPYD information sheet [pdf] 675KB.